^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)

    i
    Other names: CDKN2A, Cyclin Dependent Kinase Inhibitor 2A, P14ARF, CDK4I, MTS1, ARF, P16-INK4A, CDKN2, CMM2, INK4, P16, P19, P14, MLM, Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4), Cyclin-Dependent Kinase 4 Inhibitor A, Cyclin-Dependent Kinase Inhibitor 2A, Multiple Tumor Suppressor 1, Alternative Reading Frame, P16INK4a, P16INK4A, P19Arf, INK4a, MTS-1, Cell Cycle Negative Regulator Beta, CDK4 Inhibitor P16-INK4, Tumor Suppressor ARF, P16-INK4a, P16-INK4, P16INK4, P19ARF, INK4A, TP16
    2d
    Molecular factors associated with lung cancer in people living with HIV. (PubMed, Braz J Infect Dis)
    These alterations, together with oxidative stress, promote a pro-tumorigenic microenvironment. A deeper understanding of these mechanisms may enable early biomarker identification and the design of targeted preventive and therapeutic strategies for lung cancer in PLWH.
    Review • Journal
    |
    PTEN (Phosphatase and tensin homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CD4 (CD4 Molecule)
    3d
    ALK Inhibitor Response in Novel ZFPM2::ALK and TRIM24::ALK Fusion-Positive Lung Cancers: Case Report. (PubMed, JTO Clin Res Rep)
    The patient with TRIM24::ALK fusion, following durable responses to alectinib and lorlatinib, relapsed with detection of on-target ALK kinase domain mutations (F1174V, I1171N) and MYC amplification on progression. Comprehensive molecular workup, including RNA-based NGS, is essential for detecting rare but actionable ALK rearrangements and optimizing therapeutic strategy. NGS of CSF was a valuable tool for the detection of clinically suspected leptomeningeal disease and disease monitoring.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • EML4 (EMAP Like 4) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • TRIM24 (Tripartite Motif Containing 24)
    |
    ALK positive • ALK rearrangement • ALK fusion • CDKN2A deletion
    |
    Alecensa (alectinib) • Lorbrena (lorlatinib)
    3d
    UNC93B1 promotes pancreatic cancer progression through modulation of cGAS-STING signaling. (PubMed, Front Immunol)
    The strong correlation between UNC93B1 overexpression and adverse clinical outcomes underscores its potential as a dual diagnostic biomarker and therapeutic target. This work not only provides a mechanistic foundation for novel precision immunotherapies in PDAC but also establishes a robust methodological paradigm for multi-omics-driven discovery in oncology.
    Journal • IO biomarker
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDH1 (Cadherin 1) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • IFNB1 (Interferon Beta 1) • UNC93B1 (Unc-93 Homolog B1)
    3d
    NCI-2023-03181: Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=50, Recruiting, City of Hope Medical Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • KMT2D (Lysine Methyltransferase 2D) • NOTCH2 (Notch 2) • SOX11 (SRY-Box Transcription Factor 11) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2)
    |
    TP53 mutation • Chr t(11;14)
    |
    Venclexta (venetoclax) • lenalidomide • Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm)
    3d
    A Study of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants With Cervical Intraepithelial Neoplasia (clinicaltrials.gov)
    P1/2, N=44, Terminated, Antiva Biosciences | N=110 --> 44 | Trial completion date: Jun 2025 --> Oct 2025 | Recruiting --> Terminated | Trial primary completion date: Jun 2025 --> Oct 2025; Study terminated early due to Antiva business decision.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    3d
    A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy (clinicaltrials.gov)
    P2, N=45, Active, not recruiting, Eli Lilly and Company | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
    |
    CDKN2A deletion • IDH wild-type
    |
    temozolomide • Verzenio (abemaciclib)
    3d
    Heat shock response-driven signature and DNAJB11 in HCC: A multifaceted role in prognosis, immune microenvironment, ferroptosis and therapeutic sensitivity. (PubMed, J Therm Biol)
    Moreover, knockdown of DNAJB11 significantly suppressed cell growth, inhibited migratory and invasive capacities, and enhanced RSL3-induced ferroptosis. This study provides the first comprehensive analysis of HSR in HCC, offering a novel molecular classification and prognostic tool to guide personalized treatment strategies.
    Journal • IO biomarker
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CD4 (CD4 Molecule)
    |
    RSL3
    4d
    Prognostic Implications of Codon-Specific KRAS Mutations in Localized and Advanced Stages of Pancreatic Cancer. (PubMed, JCO Precis Oncol)
    These findings demonstrated that codon-specific KRAS mutations affect PDAC outcomes differently based on disease stage at diagnosis. As studies testing KRAS inhibitors continue to emerge and mature, the prognostic variability of individual KRAS mutations must be carefully considered to avoid confounding and ensure accurate evaluation of therapeutic efficacy in early-phase studies.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • SMAD4 (SMAD family member 4)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    4d
    Real-World Genomic Landscape of Korean Gastric Cancer: Integrating Biomarker Associations and Clinical Outcomes in Metastatic Gastric Cancer. (PubMed, JCO Precis Oncol)
    Our findings provide a comprehensive genomic landscape of Korean gastric cancer and underscore the clinical relevance of integrating genomic and established biomarkers to advance precision oncology.
    Clinical data • Journal • Real-world evidence • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • MET (MET proto-oncogene, receptor tyrosine kinase) • FGFR2 (Fibroblast growth factor receptor 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • CCNE1 (Cyclin E1) • BCOR (BCL6 Corepressor)
    |
    TP53 mutation • TMB-H • HER-2 amplification • PIK3CA mutation • ARID1A mutation • FGFR2 mutation • TMB-L • EGFR positive
    |
    Opdivo (nivolumab)
    4d
    Pinus morrisonicola induces cell-cycle arrest in human lung adenocarcinoma by modulating cyclins and cyclin-dependent kinases via p53-dependent signaling pathway. (PubMed, 3 Biotech)
    Furthermore, PMLE treatment significantly activated p53 in A549 cells, followed by increased nuclear translocation, which may account for the up regulation of p16INK4a, p21Cip1, and p27Kip1 proteins. Taken together, our results indicate that PMLE exerts anti-cancer activity in human lung adenocarcinoma by arresting the cell cycle through activation of the p53-dependent pathway.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • CDK2 (Cyclin-dependent kinase 2) • CDK1 (Cyclin-dependent kinase 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • CCNB1 (Cyclin B1)
    4d
    TUVASTRAT: Tuvusertib in Astrocytoma With ATRX Mutation (clinicaltrials.gov)
    P2, N=56, Recruiting, Grupo Español de Investigación en Neurooncología
    New P2 trial
    |
    TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ATRX (ATRX Chromatin Remodeler)
    |
    TP53 mutation
    |
    tuvusertib (M1774)
    4d
    Induction of senescence during postpartum mammary gland involution supports tissue remodeling and promotes postpartum tumorigenesis. (PubMed, Nat Aging)
    Mechanistically, senescent cells enhance tumor cell plasticity via the senescence-associated secretory phenotype, fostering metastasis. Our findings reveal that senescence, while required for postpartum tissue remodeling, can be hijacked to facilitate tumorigenesis, defining senescence as a unifying mechanism linking tissue repair to tumorigenesis.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)